Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Politics for Pros- moderated -- Ignore unavailable to you. Want to Upgrade?

To: D. Long who wrote (606148)	8/26/2016 2:48:43 PM
From: DewDiligence_on_SI	1 Recommendation Recommended By bentway Read Replies (3) \| Respond to of 793670

Government regulation of a fancy needle which effectively prevents competition. Wrong—FDA does not require a "fancy needle" to administer epinephrine; any company can apply for FDA approval to sell epinephrine with its own injection device. What's at issue in this thread (on government conspiracies) is the FDA's rejection of Teva's application to sell a generic version of Mylan's Epipen—i.e. a product that would be automatically substitutable for Mylan's EpiPen by any pharmacist. There is much misinformation about the FDA on this message board.